GLP-1 and Tirzepatide for Obesity in Teens and Older Adults: What the Evidence Shows
Liraglutide, semaglutide, and tirzepatide show obesity treatment promise in adolescents and elderly — two populations underrepresented in initial clinical trials.
Quick Facts
What This Study Found
GLP-1 RAs and tirzepatide show promising efficacy and safety in adolescent and elderly obesity populations, though evidence is more limited than in middle-aged adults.
Key Numbers
Reviews liraglutide, semaglutide, and tirzepatide data in adolescents and elderly. Discusses emerging molecules in development.
How They Did This
Review of clinical development, efficacy, safety, and tolerability data for GLP-1 RAs and tirzepatide specifically in adolescent and elderly populations.
Why This Research Matters
Teens and older adults have distinct obesity-related health risks and treatment considerations. Ensuring these medications are safe and effective in these groups is essential for responsible prescribing.
The Bigger Picture
As GLP-1 drug prescribing expands to all age groups, age-specific evidence becomes critical for guiding treatment decisions and identifying unique risks or benefits.
What This Study Doesn't Tell Us
Limited clinical trial data in both age extremes. Long-term effects on adolescent growth/development and elderly sarcopenia/frailty are not well-studied.
Questions This Raises
- ?Does weight loss with GLP-1 drugs in elderly patients increase fall or fracture risk from muscle loss?
- ?Are the metabolic benefits of obesity treatment in adolescents maintained into adulthood?
Trust & Context
- Key Stat:
- Underrepresented populations Adolescents and elderly were largely excluded from initial obesity drug trials, leaving gaps in age-specific evidence
- Evidence Grade:
- Review of available clinical data — evidence quality varies by drug and age group. Adolescent data is growing while elderly-specific data remains sparse.
- Study Age:
- Published in 2025, synthesizing the most current age-specific evidence for obesity pharmacotherapy.
- Original Title:
- GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly.
- Published In:
- Medicina clinica, 165(4), 107122 (2025)
- Authors:
- Pérez López, Gilberto
- Database ID:
- RPEP-13126
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Are GLP-1 drugs safe for teenagers?
Emerging evidence shows GLP-1 drugs can be effective for adolescent obesity, and some are now approved for teens. However, long-term effects on growth and development are still being studied.
Should elderly patients take weight loss drugs?
Weight loss in older adults carries unique risks including muscle loss and frailty. GLP-1 drugs may be appropriate for some elderly patients, but careful assessment of muscle mass and fall risk is important.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13126APA
Pérez López, Gilberto. (2025). GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly.. Medicina clinica, 165(4), 107122. https://doi.org/10.1016/j.medcli.2025.107122
MLA
Pérez López, Gilberto. "GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the treatment of obesity in adolescents and the elderly.." Medicina clinica, 2025. https://doi.org/10.1016/j.medcli.2025.107122
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 receptor agonists and GIP/GLP-1 co-agonists in the tre..." RPEP-13126. Retrieved from https://rethinkpeptides.com/research/perez-2025-glp1-receptor-agonists-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.